Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
